Prostate Cancer Guide 2026: PSA Screening, Symptoms, Diagnosis, Treatment, and Costs

"Learn about prostate cancer symptoms, PSA screening, diagnosis, stages, treatment options, side effects, and Medicare coverage in the United States."

EDITOR EA October 10, 2026

A doctor performs a prostate ultrasound examination on a male patient in a urology clinic.

Illustration of a man undergoing a prostate ultrasound examination with a physician in a urology clinic.

Prostate cancer is one of the most commonly diagnosed cancers among men in the United States. It often grows slowly, but some forms can be aggressive and spread beyond the prostate.

Understanding risk factors, screening options, diagnostic tests, and treatment choices can help patients make informed decisions with their healthcare providers.

The American Cancer Society (ACS) estimates that approximately 333,830 new prostate cancer cases and 36,320 deaths will occur in the United States in 2026. These are annual estimates, not final counts. About 1 in 8 men will be diagnosed with prostate cancer during their lifetime, although individual risk varies.

There is no single screening or treatment approach that is right for every person. A prostate-specific antigen (PSA) blood test may help identify men who need further evaluation, but an elevated PSA level does not automatically mean cancer is present.

When cancer is diagnosed, the appropriate treatment depends on factors such as the tumor's grade, stage, risk category, overall health, and personal preferences.

This guide explains what men in the United States should know about prostate cancer in 2026, including screening, symptoms, PSA testing, diagnosis, treatment, side effects, and Medicare coverage.

What Is Prostate Cancer?

The prostate is a small gland in the male reproductive system, located below the bladder and in front of the rectum. It produces fluid that forms part of semen.

Prostate cancer develops when cells in the prostate begin to grow abnormally. Many prostate cancers are adenocarcinomas, which develop in glandular cells.

Some prostate cancers grow slowly and may never cause symptoms or become life-threatening. Others can grow more rapidly, invade nearby tissues, or spread to distant parts of the body.

This difference in behavior is important. Detecting prostate cancer does not automatically mean immediate surgery or radiation is necessary. Some men with lower-risk disease may be candidates for active surveillance, while others need treatment.

What Are the Symptoms of Prostate Cancer?

Early prostate cancer often causes no symptoms. When symptoms occur, they can overlap with those of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate, or other urinary conditions.

Possible symptoms include:

Difficulty starting urination.
A weak or interrupted urine stream.
Urinating more frequently, especially at night.
Difficulty emptying the bladder completely.
Blood in the urine or semen.
Erectile dysfunction in some cases.
Persistent pain in the back, hips, or pelvis, particularly in advanced disease.

These symptoms do not necessarily indicate cancer. BPH, urinary tract problems, inflammation, and other conditions can produce similar symptoms.

Seek urgent medical attention if you cannot urinate. New severe back pain accompanied by leg weakness, numbness around the groin, or loss of bladder or bowel control also requires emergency assessment.

If you have persistent urinary symptoms, blood in your urine, or unexplained ongoing pain, contact a healthcare professional rather than relying on a screening test alone.

Who Is at Higher Risk of Prostate Cancer?

Several factors are associated with an increased risk of developing prostate cancer.

Age

Risk increases with age. Prostate cancer is uncommon in men younger than 40, and approximately 6 in 10 diagnoses occur in men age 65 or older, according to the ACS.

Family history

Having a father, brother, or other close relative with prostate cancer can increase risk, particularly when the relative was diagnosed at a younger age or several family members have had the disease.

A family history of breast, ovarian, pancreatic, or other cancers may also be relevant because certain inherited genetic changes can increase prostate cancer risk.

Inherited genetic changes

Some inherited variants, including changes in BRCA2 and BRCA1, are associated with a higher risk of prostate cancer. Other genes may also be relevant in selected families.

Genetic counseling or testing may be appropriate for some men, especially those with a strong family history or advanced disease.

Race and ethnicity

Black men in the United States have a higher incidence of prostate cancer and are more likely to die from the disease than White men. The reasons are complex and include biological, social, healthcare-access, and other factors.

Men at increased risk should discuss the timing of screening with their healthcare provider rather than assuming that the same approach is appropriate for everyone.

What Is a PSA Test?

A prostate-specific antigen test measures the amount of PSA in the blood. PSA is a protein produced by prostate tissue.

Doctors may use PSA testing to help assess prostate cancer risk, investigate possible disease, or monitor patients after diagnosis or treatment.

However, PSA is not a cancer-specific marker. PSA levels can rise because of prostate cancer, BPH, inflammation, infection, or other factors.

Some men with prostate cancer also have PSA levels that are not markedly elevated.

A PSA result must therefore be interpreted in context.

What is a normal PSA level?

There is no single PSA cutoff that can definitively distinguish prostate cancer from noncancerous conditions in every patient.

A result that falls within a laboratory's reference range does not completely rule out cancer, and an elevated result does not establish a diagnosis.

Doctors may consider the PSA value, age, previous results, prostate size, medications, family history, symptoms, and other clinical findings. Depending on the situation, they may recommend repeating the test, using additional risk assessment tools, obtaining an MRI, or considering a biopsy.

Read our dedicated guide: What Is a PSA Test? Normal Levels by Age

When Should Men Get Screened for Prostate Cancer?

There is no universal screening schedule that applies to every man. Recommendations differ, and major organizations emphasize the importance of discussing the potential benefits and harms before testing.

The USPSTF's published recommendation advises individualized decision-making for men ages 55–69 and recommends against routine PSA-based screening for men age 70 and older. The USPSTF page also indicates that this recommendation is being updated, so readers should check the current guidance before making a decision.

Screening discussions may be appropriate earlier for men at higher risk, including Black men and those with a strong family history or certain inherited genetic variants. The appropriate starting age and frequency should be individualized.

Why is screening a personal decision?

PSA screening can identify cancer before symptoms develop, but it also has potential harms.

These include:

False-positive results that lead to additional testing.
Biopsies that may cause discomfort, bleeding, infection, or other complications.
Detection of cancers that would never have caused symptoms or shortened life.
Treatment-related urinary, sexual, or bowel side effects.

The decision should take into account a person's risk factors, general health, life expectancy, preferences, and willingness to undergo further testing or treatment if a result is abnormal.

Screening is intended for people without symptoms. If symptoms are present, a clinician may recommend diagnostic evaluation regardless of routine screening recommendations.

What Happens After an Elevated PSA Result?

An elevated PSA result does not automatically mean that a patient needs a prostate biopsy.

The next step depends on the PSA level, previous results, risk factors, possible noncancerous causes, and the clinician's assessment.

Possible next steps include:

Repeat PSA testing. A clinician may repeat the test to determine whether the elevation persists, particularly if a temporary cause is possible.
Review other risk factors. Family history, medications, urinary symptoms, and other clinical information may influence the assessment.
Use additional risk assessment. Depending on the situation, a doctor may consider a risk calculator, a secondary biomarker test, or other tools.
Consider prostate MRI. Multiparametric MRI can help identify areas that may warrant closer evaluation and guide decisions about biopsy.
Discuss a prostate biopsy. A biopsy may be recommended when the overall likelihood of clinically significant cancer justifies the procedure.

Not every patient needs every step. The sequence varies according to clinical findings and local practice.

How Is Prostate Cancer Diagnosed?

Diagnosis generally involves a combination of medical history, examination, laboratory testing, imaging, and, when indicated, a biopsy.

Digital rectal examination

During a digital rectal examination (DRE), a healthcare professional inserts a gloved, lubricated finger into the rectum to feel the prostate for abnormalities.

A DRE may provide additional clinical information, but it cannot rule out prostate cancer on its own.

Prostate MRI

Multiparametric MRI uses several imaging sequences to assess the prostate and identify suspicious areas. It can help guide decisions about whether a biopsy is needed and where samples should be taken.

MRI findings do not provide a definitive cancer diagnosis. Some suspicious areas are not cancer, and some cancers may not be clearly visible.

Prostate biopsy

A biopsy involves collecting small tissue samples from the prostate for examination by a pathologist.

A biopsy is commonly performed using a needle, with imaging guidance when appropriate. The procedure may be performed through the perineum or rectum, depending on the approach used.

Potential risks include bleeding, pain, urinary problems, and infection. Patients should ask about preparation, medication management, recovery, and warning signs after the procedure.

Pathology and Grade Group

If cancer is identified, the pathology report may include a Gleason score and Grade Group. These measurements describe how abnormal the cancer cells look and help estimate how aggressively the cancer may behave.

The result is considered alongside PSA, imaging, clinical stage, and other information to guide risk classification and treatment planning.

What Are the Stages of Prostate Cancer?

Staging describes how far the cancer has spread. The stage helps doctors estimate prognosis and determine which treatments may be appropriate.

Stage I: The cancer is generally localized and may have features associated with lower-risk disease.
Stage II: The cancer remains within the prostate but may have a greater tumor burden or higher-risk features.
Stage III: The cancer may have grown beyond the prostate or have other features associated with locally advanced disease.
Stage IV: The cancer has spread to nearby structures, lymph nodes, or distant sites, depending on the specific stage classification.

These descriptions are simplified. Prostate cancer staging includes additional categories and clinical details, and the stage alone does not determine the treatment.

Doctors may use PSA, Grade Group, physical examination, MRI, and other imaging tests to establish the stage and risk group.

For more information, see the National Cancer Institute's prostate cancer treatment and staging overview.

What Are the Treatment Options for Prostate Cancer?

Treatment depends on the cancer's risk category, stage, symptoms, overall health, expected benefits, potential side effects, and patient preferences.

Active surveillance

Active surveillance involves closely monitoring prostate cancer that is considered suitable for observation, with the intention of starting curative treatment if the disease shows signs of progression.

Monitoring may include PSA tests, examinations, MRI, and repeat biopsies, depending on the patient's risk category and care plan.

It is not the same as ignoring the cancer. The goal is to avoid or delay treatment-related side effects when immediate treatment is unlikely to provide enough additional benefit.

Watchful waiting

Watchful waiting generally focuses on monitoring symptoms and providing treatment to maintain quality of life if the disease causes problems.

It may be appropriate for some older patients or those with other serious health conditions, depending on their circumstances.

The distinction between watchful waiting and active surveillance is important: active surveillance usually aims to preserve the opportunity for curative treatment if the cancer progresses, while watchful waiting generally emphasizes symptom management.

Surgery

A radical prostatectomy removes the prostate gland and, in some cases, nearby tissue or lymph nodes.

Surgery may be considered for selected patients whose cancer is localized or locally advanced and who are suitable candidates for the procedure.

Possible side effects include urinary incontinence, erectile dysfunction, bleeding, infection, and complications related to anesthesia or surgery. The likelihood and severity vary by patient and surgical approach.

Radiation therapy

Radiation therapy uses high-energy radiation to damage cancer cells. It may be delivered externally or, in selected patients, through radioactive sources placed in or near the prostate.

Radiation may be used alone or combined with hormone therapy, depending on the cancer's risk and stage.

Potential side effects include urinary irritation, bowel symptoms, fatigue, and sexual dysfunction. Some effects can persist or develop later.

Hormone therapy

Hormone therapy, also called androgen deprivation therapy (ADT), reduces or blocks the effects of hormones that can stimulate prostate cancer growth.

It may be used with radiation, for advanced disease, or in other treatment settings.

Side effects can include hot flashes, reduced libido, erectile dysfunction, fatigue, changes in body composition, bone loss, and metabolic effects. The risks depend on the medication, duration, and individual health.

Chemotherapy, targeted therapy, and radiopharmaceuticals

For selected patients with advanced or metastatic prostate cancer, treatment may include chemotherapy, targeted drugs, immunotherapy in particular circumstances, or radiopharmaceutical treatments.

Molecular testing may help identify patients who could benefit from certain targeted treatments. The relevance of a biomarker depends on the exact tumor alteration and the drug's approved indication.

These treatments are not appropriate for every patient. An oncologist can explain which options match the cancer's characteristics and previous treatment history.

The NCI provides a more detailed overview of prostate cancer treatment options.

What Are the Side Effects of Prostate Cancer Treatment?

The potential side effects depend on the treatment, the patient's baseline health, and the cancer itself.

Common concerns include:

Urinary changes: leakage, urgency, irritation, or difficulty urinating.
Sexual effects: erectile dysfunction or reduced sexual desire.
Bowel effects: diarrhea, rectal irritation, or other changes, particularly after some forms of radiation.
Hormonal effects: hot flashes, fatigue, loss of muscle mass, weight changes, and reduced bone density.
Emotional and relationship effects: anxiety, changes in body image, and concerns about sexual function or independence.

Patients should ask their care team about the likelihood of these effects, whether they may improve over time, and what rehabilitation or supportive care is available.

Treatment decisions should balance cancer control with quality of life. For some patients, avoiding or delaying treatment-related harm is an important consideration; for others, the expected benefits of active treatment may outweigh those risks.

Does Medicare Cover Prostate Cancer Screening?

Yes. Medicare Part B covers eligible prostate cancer screening services once every 12 months.

According to Medicare.gov, eligible men age 50 and older can receive a covered PSA blood test and digital rectal examination under the program's screening rules.

The costs differ by service:

PSA blood test: You pay nothing for the covered test when Medicare's requirements are met. If the provider does not accept assignment, you may owe an additional fee for the provider's services.
Digital rectal examination: After meeting the Part B deductible, you generally pay 20% of the Medicare-approved amount for the examination and related physician services. A hospital outpatient copayment may also apply.

Screening coverage is different from diagnostic testing after an abnormal result and from treatment following a cancer diagnosis. Additional blood tests, imaging, biopsy, surgery, radiation, or drug therapy may have separate coverage and cost-sharing rules.

Medicare Advantage plans must cover Medicare-covered preventive services, but network and administrative requirements may differ. Confirm the details with your plan before scheduling.

How Much Does Prostate Cancer Treatment Cost?

There is no single cost for prostate cancer treatment in the United States. Total expenses depend on the stage of disease, treatment approach, provider, location, insurance plan, medications, follow-up care, and possible complications.

A patient who chooses active surveillance may have recurring costs for appointments, PSA tests, imaging, or biopsies. Someone undergoing surgery or radiation may have different costs, including facility and physician services. Advanced disease can involve ongoing medication, infusion, imaging, or other treatment expenses.

Before starting treatment, ask the provider and insurer for an estimate that distinguishes:

Facility charges.
Surgeon, oncologist, radiologist, and other professional fees.
Imaging and laboratory tests.
Prescription medicines.
Follow-up visits and monitoring.
Deductibles, copayments, and coinsurance.
Out-of-network charges, if applicable.

If the estimated costs are difficult to manage, ask about financial counseling, hospital assistance programs, and other resources.

A separate supporting article will cover how much prostate cancer treatment costs in the United States, including Medicare and self-pay considerations.

Questions to Ask Your Healthcare Provider

Whether you are considering screening, undergoing further testing, or deciding on treatment, the following questions may help guide the conversation:

What is my personal risk of prostate cancer?
What are the potential benefits and harms of PSA screening in my situation?
If my PSA is elevated, what could be causing it?
Would repeat testing, MRI, or a biopsy be appropriate?
If cancer is found, what are my Grade Group, stage, and risk category?
Is active surveillance an option, or is immediate treatment recommended?
How might each treatment affect urinary function, sexual health, and quality of life?
Would genetic or biomarker testing change my treatment options?
What will my insurance cover, and what out-of-pocket costs should I expect?
Would a second opinion help me compare treatment options?

The Bottom Line

Prostate cancer ranges from slow-growing disease that may be monitored to aggressive cancer that requires active treatment. PSA testing can help identify men who may need further evaluation, but it cannot diagnose cancer on its own.

The most appropriate approach depends on personal risk, screening preferences, diagnostic findings, cancer stage, and the likely benefits and harms of available treatments. Medicare covers eligible screening services, but diagnostic testing and treatment may involve different costs.

Discuss screening and treatment decisions with a qualified healthcare professional who can review your medical history and individual circumstances.

Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Screening and treatment decisions should be made with a qualified healthcare professional.

Source review date: October 11, 2026. Statistics, screening guidance, treatment information, and Medicare coverage were reviewed against the American Cancer Society, National Cancer Institute, U.S. Preventive Services Task Force, and Medicare.gov. Screening recommendations can change; confirm the latest guidance before making a medical decision.